A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Clinical trial NCT06433752 · RECRUITING
Trial details
- NCT number
- NCT06433752
- Sponsor
- TG Therapeutics, Inc.
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-07-22
- Primary completion
- 2032-04-01
- Enrollment
- 2000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.